论文部分内容阅读
目的探讨艾愈胶囊预防肺癌放化疗所致并发症的效果及安全性。方法选取2014年7月至2015年6月间收治的60例拟行放化疗的非小细胞肺癌患者,按照随机数字表法分为观察组(28例)和对照组(32例),两组患者均行紫杉醇+奈达铂(TP方案)化疗,并于2个月后行三维适形放疗,放化疗间歇期均酌情应用粒细胞集落刺激因子(G-CSF)皮下注射。在此基础上,观察组患者自化疗开始即口服艾愈胶囊3粒/次、3次/d,持续至放疗结束。观察两组患者治疗前后外周血白细胞计数变化、白细胞减少分度及艾愈胶囊的不良作用。结果治疗后14、21d,观察组患者白细胞计数分别为(4.70±1.35)×10~9/L和(5.33±1.68)×10~9/L,显著高于对照组的(3.64±1.52)×109/L和(3.88±1.73)×10~9/L,差异有统计学意义(P<0.01)。观察组中重度骨髓抑制(Ⅲ+Ⅳ度)患者6例,发生率为21.4%,显著低于对照组的46.9%,差异有统计学意义(P<0.05)。观察组恶心呕吐等不良反应发生率为17.9%,明显低于对照组的56.3%,差异有统计学意义(P<0.05),但两组患者在肝肾功能损伤方面差异无统计学意义(P>0.05)。结论艾愈胶囊预防非小细胞肺癌放化疗所致外周血白细胞减少效果确切,安全性好。
Objective To investigate the efficacy and safety of Aiyu capsule in preventing complications caused by radiotherapy and chemotherapy of lung cancer. Methods Sixty non-small cell lung cancer patients scheduled for chemoradiotherapy admitted from July 2014 to June 2015 were divided into observation group (n = 28) and control group (n = 32) according to random number table method. Two groups All patients underwent chemotherapy with paclitaxel plus nedaplatin (TP regimen). Three-dimensional conformal radiotherapy was performed after 2 months. G-CSF was injected subcutaneously as appropriate during the interval of chemoradiotherapy. On this basis, the observation group of patients from the beginning of chemotherapy that oral Aiyu capsule 3 / time, 3 times / d, continued until the end of radiotherapy. The changes of peripheral white blood cell count, leukopenia index and the adverse effects of AI Yu capsule before and after treatment were observed in two groups of patients. Results On the 14th and 21st day after treatment, the white blood cell counts of the observation group were (4.70 ± 1.35) × 10 ~ 9 / L and (5.33 ± 1.68) × 10 ~ 9 / L respectively, which were significantly higher than those of the control group (3.64 ± 1.52) × 109 / L and (3.88 ± 1.73) × 10 ~ 9 / L, respectively, with statistical significance (P <0.01). In the observation group, 6 patients with severe myelosuppression (Ⅲ + Ⅳ degree) had a rate of 21.4%, which was significantly lower than 46.9% of the control group (P <0.05). The incidence of adverse reactions such as nausea and vomiting in the observation group was 17.9%, which was significantly lower than that in the control group (56.3%) (P <0.05), but there was no significant difference between the two groups in liver and kidney function damage (P > 0.05). Conclusion AI Yu Capsule is effective in preventing peripheral leukopenia caused by chemoradiation and chemotherapy in non-small cell lung cancer.